Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Phase I/II trial of alectinib in pediatric patients with ALK-fusion tumors

Francois Doz • 1 Jun 2025
ASCO 2025
General Alectinib
iMATRIX Alectinib

Francois Doz, MD, Institut Curie, Paris, France, discusses the Phase I/II iMATRIX Alectinib trial (NCT04774718) of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors. The study reports a favorable safety profile, with most adverse events being low grade. Promising antitumor activity was observed across both CNS and solid tumor types, including in treatment-naïve patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francois Doz

Precision medicine in pediatric cancer treatment
1:23
Precision medicine in pediatric cancer treatment
Francois Doz • 1 Jun 2025

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals